SCHEMBL9890726

SCHEMBL9890726

COc1ccc(-c2ccccc2)c(CC(N)=O)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G10 O15496 1/20 0.52
PLA2G2A P14555 7/20 0.51
KDM4E B2RXH2 2/20 0.49
MEN1 O00255 1/20 0.49
MAPT P10636 1/20 0.49
KMT2A Q03164 1/20 0.49
BACE1 P56817 2/20 0.48
HSD17B10 Q99714 2/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
ALDH1A1 P00352 1/20 0.47
LMNA P02545 1/20 0.47
HPGD P15428 1/20 0.47
TSHR P16473 1/20 0.47
TAS1R3 Q7RTX0 1/20 0.46
TAS1R1 Q7RTX1 1/20 0.46
PPARG P37231 2/20 0.45
MTNR1A P48039 1/20 0.45
MTNR1B P49286 1/20 0.45
BAZ2B Q9UIF8 1/20 0.44
BAZ2A Q9UIF9 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9890648 0.88 HSD17B10 (0.62) KDM4EMAPTBACE1HSD17B10SMN1; SMN2
SCHEMBL9892666 0.82 FFAR4 (0.45)
SCHEMBL9890742 0.81 MTNR1A (0.50) PLA2G10PLA2G2AKDM4EMAPTKMT2A
SCHEMBL4961133 0.81 PTPN1 (0.50) KDM4EMEN1MAPTKMT2ABACE1
SCHEMBL27821291 0.81 BAZ2B (0.53) KDM4EMEN1MAPTKMT2ABACE1
SCHEMBL9890761 0.80 PTGDR2 (0.47) KDM4EKMT2AALDH1A1HPGD
SCHEMBL3738351 0.80 HSD17B10 (0.64) KDM4EMAPTBACE1HSD17B10SMN1; SMN2
SCHEMBL8771914 0.79 KIF11 (0.46) MEN1KMT2ABACE1SMN1; SMN2TAS1R3
Hydrochloric Acid SCHEMBL7570098 0.78 TPH1 (0.45) MEN1KMT2ABACE1SMN1; SMN2TAS1R3
SCHEMBL2391307 0.77 FFAR1 (0.49) MAPTKMT2APPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 PLA2G10 2343/4885PLA2G2A 2159/4885KDM4E 829/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 PLA2G10 2343/4885PLA2G2A 2159/4885KDM4E 829/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.